Efficacy of continuous glucose monitoring in people living with diabetes and end stage kidney disease on dialysis: a systematic review
Zhang, Yimeng Singh, Pushpa Ganapathy, Kavitha Suresh, Vijayan Karamat, Muhammad Ali Baharani, Jyoti Bellary, Srikanth
Zhang, Yimeng
Singh, Pushpa
Ganapathy, Kavitha
Suresh, Vijayan
Karamat, Muhammad Ali
Baharani, Jyoti
Bellary, Srikanth
An error occurred retrieving the object's statistics
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2024-10-25
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Patients with diabetes on dialysis experience wide variations in glucose levels and an increased risk of hypoglycaemia. Due to the inaccuracies of HbA1c in dialysis patients, JBDS-IP and KDIGO recommend the use of continuous glucose monitoring (CGM). We conducted a systematic review to examine the current evidence for CGM use and its impact on clinical outcomes in patients with diabetes on dialysis.
Methods: A search of MEDLINE(R) ALL, Ovid Emcare, Journals@Ovid Full Text and Embase databases were conducted. Clinical or observational trials in adults with Type 1(T1D) or Type 2 (T2D) diabetes on dialysis and CGM intervention reporting on glycaemic outcomes were included.
Results: Of the 936 citations identified, 49 duplicates were removed. 887 citations were screened by title and abstract. 9 full texts were reviewed and a further 7 excluded due to duplications or failure to meet to selection criteria. Data was extracted for 2 studies, both prospective before-and-after interventional studies with no control group. Joubert et al. (2015) showed results for 15 participants with T1D. Mean CGM glucose level decreased from 8.37mmol/L at baseline to 7.7mmol/L at the end of the CGM period (p < 0.05) while HbA1c decreased from 6.9 to 6.5% (p < 0.05) during the same period. Mean CGM was lower on dialysis days (7.68mmol/L vs. 7.8mmol/L, p < 0.05). Képénékian et al. (2014) reported on data from 29 T2D patients. Following a 3 month CGM-adapted insulin regimen, HbA1c decreased from 8.4% at baseline to 7.6% (p < 0.01) by the end of study. Mean CGM values decreased from 9.9mmol/L to 8.9mmol/L (p = 0.05) and the frequency of glucose values > 10mmol/L decreased from 41 to 30% (p < 0.05), without a significant increase in hypoglycaemia frequency. Both studies were deemed to be of 'good' quality.
Conclusion: Evidence demonstrating the benefits of CGM in patients with diabetes receiving dialysis is lacking. There is a need for well-designed randomised controlled trials to ascertain the benefits of this technology in this patient group.
Trail registration: PROSPERO registration number: CRD42023371635, https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=371635 .
Citation
Zhang Y, Singh P, Ganapathy K, Suresh V, Karamat MA, Baharani J, Bellary S. Efficacy of continuous glucose monitoring in people living with diabetes and end stage kidney disease on dialysis: a systematic review. BMC Nephrol. 2024 Oct 25;25(1):379. doi: 10.1186/s12882-024-03763-z.
Type
Article